Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Scynexis has gained global development and commercialization rights to novel antifungal compound MK-3118 from Merck, referred to as MSD outside the US and Canada.
Subscribe to our email newsletter
The oral glucan synthase inhibitor being developed for the treatment of systemic fungal diseases completed Phase I studies and is ready to enter Phase IIb studies.
Scynexis president and chief executive officer Yves Ribeill said, "The addition of this anti-fungal platform to our portfolio expands our pipeline and positions SCYNEXIS as a leading anti-infective company."
Under the agreement, all rights to MK-3118 including pre-clinical, IND and Phase I data packages will be transferred to Scynexis while Merck is eligible for milestones and royalties.
Merck worldwide licensing and knowledge management senior vice president and head Roger Pomerantz said, "Merck continues to advance its infectious disease pipeline and remains committed to delivering medicines in this important therapeutic area."
In 2002, Scynexis and Merck signed exclusive license and research agreement aimed at developing antifungal treatments against invasive fungal infections including Candida and Aspergillus.